Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 1
1963 1
1964 2
1968 1
1971 1
1972 2
1973 1
1976 1
2000 1
2001 2
2002 3
2004 3
2005 3
2006 2
2007 7
2008 14
2009 4
2010 6
2011 8
2012 8
2013 3
2014 3
2015 6
2016 10
2017 10
2018 12
2019 10
2020 16
2021 12
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

147 results
Results by year
Filters applied: . Clear all
Page 1
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
[Oncolytic coxsackievirus therapy as an immunostimulator].
Miyamoto S, Sagara M, Kohara H, Tani K. Miyamoto S, et al. Rinsho Ketsueki. 2017;58(8):977-982. doi: 10.11406/rinketsu.58.977. Rinsho Ketsueki. 2017. PMID: 28883283 Review. Japanese.
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better understand its pathogenicity. In particular, coxsackievirus A21 (CVA21) is a promising candidate for oncolytic virotherapy, and thus is the focus o …
Recently, the active development of oncolytic virotherapy has gathered attention. Enterovirus research seeks to better understand its …
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competent oncolytic viruses and replication-deficient viral vectors. Oncolytic viruses are designed to selectively target, infect, and …
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competen …
Oncolytic viral therapy.
Inam Ur Rehma S, Haaris SM. Inam Ur Rehma S, et al. J Pak Med Assoc. 2017 Apr;67(4):658. J Pak Med Assoc. 2017. PMID: 28420939 Free article. No abstract available.
Oncolytic Seneca Valley Virus: past perspectives and future directions.
Burke MJ. Burke MJ. Oncolytic Virother. 2016 Sep 6;5:81-9. doi: 10.2147/OV.S96915. eCollection 2016. Oncolytic Virother. 2016. PMID: 27660749 Free PMC article. Review.
Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first picornavirus discovered of the novel genus Senecavirus. ...This review summarizes the current knowledge of SVV-001 and what its future as an …
Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first pico
Rescue of NanoLuc luciferase-expressing Senecavirus A with oncolytic activity.
Liu F, Wang Q, Huang Y, Wang N, Shan H. Liu F, et al. Virus Res. 2021 Jan 15;292:198232. doi: 10.1016/j.virusres.2020.198232. Epub 2020 Nov 15. Virus Res. 2021. PMID: 33207264
Senecavirus A (SVA), previously known as Seneca Valley virus, is classified into the genus Senecavirus in the family Picornaviridae. SVA is not pathogenic to normal human cells, but has potent oncolytic activity in some tumor cells with neuroendocrine feature, such …
Senecavirus A (SVA), previously known as Seneca Valley virus, is classified into the genus Senecavirus in the family Picornaviridae. …
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu M, Armstrong EJL, Jennings V, Foo S, Crespo-Rodriguez E, Bozhanova G, Patin EC, McLaughlin M, Mansfield D, Baker G, Grove L, Pedersen M, Kyula J, Roulstone V, Wilkins A, McDonald F, Harrington K, Melcher A. Chiu M, et al. Expert Opin Biol Ther. 2020 Jun;20(6):635-652. doi: 10.1080/14712598.2020.1729351. Epub 2020 Feb 23. Expert Opin Biol Ther. 2020. PMID: 32067509 Review.
However the response rates to ICI monotherapy remain relatively low, in part due to some tumors cultivating an inherently 'cold' immune microenvironment. Oncolytic viruses (OV) have the capability to promote a 'hotter' immune microenvironment which can improve the efficacy …
However the response rates to ICI monotherapy remain relatively low, in part due to some tumors cultivating an inherently 'cold' immune micr …
The advent of oncolytic virotherapy in oncology: The Rigvir® story.
Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. Alberts P, et al. Eur J Pharmacol. 2018 Oct 15;837:117-126. doi: 10.1016/j.ejphar.2018.08.042. Epub 2018 Sep 1. Eur J Pharmacol. 2018. PMID: 30179611 Free article. Review.
Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are approved. ...Several immunological markers have been measured. In conclusion, Rigvir is an oncotropic and oncolytic virus for treatment
Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are ap
Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
Sagara M, Miyamoto S, Itoh S, Soda Y, Tani K. Sagara M, et al. Anticancer Res. 2021 Jan;41(1):81-89. doi: 10.21873/anticanres.14753. Anticancer Res. 2021. PMID: 33419801
MATERIALS AND METHODS: We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated that miRNA target sequence insertion into CVB3 reduced its pathogenicity, retaining its original oncolytic activity. In this study, we examine …
MATERIALS AND METHODS: We previously developed a new Coxsackievirus B3 (CVB3) virotherapy targeting lung cancers, and demonstrated that miRN …
147 results